Introduction
Receptors that mediate the effects of growth hormone secretagogues (GHSs), including modified enkephalin peptides (Bowers et al, 1984) as well as small molecules (Smith et al, 1993) , each capable of stimulating GH release, were only recently cloned (Howard et al, 1996) . Two isoforms (A and B) were identified, but only Growth Hormone Secretagogue Receptor type 1a (GHSR1a) binds and responds to GHSs (Howard et al, 1996) . Both isoforms are widely expressed, with the highest levels of GHSR1a found in the arcuate nucleus of the hypothalamus, and lower levels in cardiac tissue (Gnanapavan et al, 2002 , Guan et al, 1997 . Subsequently, a naturally occurring GHSR1a agonist was identified called ghrelin (Kojima et al, 1999) .
A great deal of evidence exists linking ghrelin, GHSR1a receptors, food intake, and obesity in both animal models (Tschop et al, 2000; Nakazato et al, 2001; Asakawa et al, 2003; Shearman et al, 2006) and humans (Wren et al, 2001; Cummings et al, 2001; . However, ghrelin also regulates a variety of other endocrine and metabolic processes including gut motility, energy homeostasis, cellular proliferation, and hormone production (reviewed in van der Lely et al, 2004) . Notably, ghrelin, and other GHS ligands produce a number of beneficial effects on cardiovascular function including reductions in vascular resistance, vasodilation, increases in microvascular flow, increases in left ventricular ejection fraction and cardiac output, and cardioprotection in ischemiareperfusion injury models (Nagaya et al, 2001; 2001b; 2001c; Benso et al, 2004; Cao et al, 2005; Bedendi et al, 2003; Baldanzi et al, 2002) . GHSR1a receptors are expressed in heart and vasculature where they may mediate the beneficial effects of ghrelin and GHS This article has not been copyedited and formatted. The final version may differ from this version. ligands, though other receptors may also contribute (Baldanzi et al, 2002; Benso et al, 2004; Cao et al, 2005; Bedendi et al, 2003) .
Diltiazem, is an L-type Ca 2+ channel blocker developed over 30 years ago (Uchida, 1976) used to treat patients suffering from angina pectoris, conjestive heart failure, chronic obstructive pulmonary disease and coronary artery spasm (Chaffman and Brogden, 1985; Glossman and Striessnig, 1990) . Diltiazem exerts its therapeutic effects by reducing vascular resistance, lowering blood pressure, increasing cardiac output, and lowering heart rate. In addition, diltiazem has been shown to provide cardioprotection against ischemia/reperfusion injury in rats (Takeo et al, 2003) , similar effects as have been noted for ghrelin and other GHSs (discussed above). Diltiazem is extensively metabolized, and several of these metabolites reach significant concentrations in humans (Molden et al, 2000; Rovei et al, 1980; Sugihara et al, 1984; Sugawara et al, 1988) .
Several metabolites of diltiazem also show binding activity at Ca 2+ channels, though all have lower affinity than diltiazem itself (Schoemaker et al, 1987) .
To better understand the molecular basis for the clinical actions of drugs, we have been systematically screening and profiling collections of clinically used compounds for activity in functional assays utilizing heterologously expressed G-protein coupled receptors (GPCRs). Using this strategy, diltiazem, and several metabolites of diltiazem were identified as novel GHSR1a agonists in a variety of in vitro and in vivo assays. The possible clinical significance of these findings is discussed.
This article has not been copyedited and formatted. The final version may differ from this version. Constructs. The GHSR1a receptor used in this study was cloned by polymerase chain reaction using oligonucleotides derived from the GenBank accession entry U60179.
Regulator of G-protein signaling 1 (RGS1) was described previously (Burstein et al, 2005) . PCRs were performed using Pfu Turbo (Stratagene, La Jolla, CA). All clones were sequence verified before use.
Cellular proliferation assays -Cellular proliferation assays (also previously referred to as Receptor Selection and Amplification Technology (R-SAT ® ) assays were performed as described (Burstein et al, 2006) with the following modifications. Briefly:
Cells were plated one day before transfection using 7 x 10 3 cells in 0. protein: MT-GFP-AEQ, as described previously (Burstein et al, 2006) .
Bioluminescence Resonance Energy Transfer (BRET-2) assays -BRET assays
were performed as described with the following modifications:
HEK293T cells cultured in 10 cm 2 plates were transiently transfected with plasmid DNAs 
where X is the logarithm of concentration. Y is the response; Y starts at Bottom and goes to Top with a sigmoid shape. Allowing the Hill coefficient to vary did not significantly change the fits of the curves and thus the Hill coefficient was constrained to unity.
Growth Hormone (GH) releasing assays -Male Sprague-Dawley neonates (~35 g, 16-day old) were housed with free access to rat chow/water at 6 animals per cage for at least 2 days prior to use. Drugs were dosed i.p. (~9:30am) in 5% DMSO-95% PEG-400
vehicle. Prior to sacrifice, rats were anesthetized with isoflurane (Aerrane, Baxter).
Trunk blood samples were collected 15 min after i.p. injection. Plasma was isolated by centrifugation at 3000 rpm for 15 min then stored at -80 °C until use. Rat GH levels were measured using rat growth hormone EIA kits (SPI-BIO, France) according to the manufacturers instructions.
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Results
We have developed a high-throughput cellular proliferation assay, which is compatible with most G-protein coupled receptors, and which detects constitutive receptor activity with high sensitivity (R-SAT ® , Burstein et al, 2005; . In order to identify novel small molecule ligands, R-SAT ® was used to screen the human GHSR1a receptor against a collection of over 200,000 compounds. The compound library included products of combinatorial chemical synthesis, medicinal chemistry synthesis, and over 2000 clinically used drugs. A large number of novel agonists and inverse agonists at the GHSR1a receptor were identified, most of which will not be described further here.
Among the 'hits' identified was the L-type Ca 2+ blocker diltiazem (Figure 1) .
Full concentration-response experiments confirmed that diltiazem is a partial agonist at GHSR1a, with about 70% efficacy compared with GHRP-6, and a potency of 400 nM (Figure 2 , Table 1 ). Diltiazem-induced responses in cellular proliferation were completely suppressed by the ghrelin-receptor inverse agonist substance P analog, verifying that diltiazem was mediating responses through activation of GHSR1a (data not shown). No significant functional response of GHSR1a receptors was observed to other Ca 2+ channel blockers verapamil, its methoxy analogue, or nifedipine ( Table 1) .
Diltiazem is extensively metabolized (Molden et al, 2000; Rovei et al, 1980; Sugihara et al, 1984; Sugawara et al, 1988 ; see Figure 1 ), and several of its metabolites also possess Ca 2+ channel blocking activity (Schoemaker et al, 1987) . Seven of the primary metabolites of diltiazem were synthesized and tested for activity at GHSR1a.
Several of the diltiazem metabolites were also agonists at GHSR1a. The M A , M 1 , and M 2
This article has not been copyedited and formatted. The final version may differ from this version. (Figure 2 , Table 1 ). The M 4 and M 6 metabolites displayed weak agonist activity at GHSR1a. The M 8 and M 9 metabolites did not display agonist activity at GHSR1a, nor were they able to block GHRP-6 induced responses indicating they did not act as antagonists at GHSR1a either (data not shown). The potencies of GHRP-6, ghrelin, and hexarelin in the cellular proliferation assay were similar to previously reported values (see Holst et al., 2005) , however ghrelin displayed surprisingly low efficacy in the cellular proliferation assay.
GHSR1a receptors couple the G-protein Gq to release intracellular Ca 2+ (Howard et al, 1996) , and like virtually all GPCRs, agonist-activated GHSR1a receptors recruit and bind β-arrestin (Holst et al, 2005) . Therefore, to verify the results obtained using the cellular proliferation assay, diltiazem and the active metabolites were tested for agonist activity at GHSR1a in Ca 2+ mobilization assays, and bioluminescence resonance energy transfer (BRET-2) assays in which luciferase-tagged receptors (GHSR1a-luc) were cotransfected with GFP-tagged β-arrestin-2 (see methods). Separate experiments verified that activity of the GHSR1a receptor in the cellular proliferation assay was not significantly altered by the presence of the luciferase tag (data not shown). The pEC 50
values of GHRP-6 in the Ca 2+ and BRET-2 assays were 9.1 and 8.4, respectively, in good agreement with its potency in the cellular proliferation assay (see Table 1 ). Similar to the cellular proliferation assay, and as seen previously in BRET-2 assays (Holst et al, 2005) , ghrelin was a partial agonist in BRET-2, though it was essentially a full agonist in Ca 2+ mobilization assays.
This article has not been copyedited and formatted. The final version may differ from this version. To directly verify that diltiazem and its primary metabolites are human GHSR1a receptor ligands, radioligand-binding assays were carried out using cell membranes expressing human GHSR1a receptors, using 125 I-ghrelin as the radioligand. Diltiazem, and its primary metabolites M A , M 1 and M 2 each completely displaced 125 I-ghrelin with a rank order of potency similar to that seen in the functional assays ( Table 2) .
A characteristic of GHSR1a agonists such as GHRP-6 is the ability to stimulate the release of growth hormone (GH) (Bowers et al, 1984) . Diltiazem and the M 2 metabolite of diltiazem were administered to male Sprague dawley neonatal rats, and plasma levels of growth hormone assessed. Both diltiazem and M 2 were able to stimulate increases in plasma GH levels, though only the increases in response to diltiazem were statistically significant ( Figure 5 , Table 3 ). The diltiazem-induced increases were approximately 40% of the maximal effect of GHRP-6
This article has not been copyedited and formatted. The final version may differ from this version. Table 2 ). In contrast, the rank order of potency of GHRP-6 and ghrelin was ghrelin > GHRP-6 in the cellular proliferation assay, in BRET-2, and in binding assays, but was reversed in Ca 2+ mobilization assays, similar to previous observations (Holst et al, 2005) . Ghrelin was a partial agonist compared with GHRP-6 in cellular proliferation and BRET-2 assays, in agreement with previous observations that ghrelin is a partial agonist in some functional assays (Holst et al, 2005) .
Further tests revealed that diltiazem, and M 2 , the most potent and efficacious GHSR1a-receptor agonist of the diltiazem metabolites, acted as GHSR1a agonists in vivo. Both diltiazem and M 2 stimulated GH-release in neonatal rats. Compared with GHRP-6, the maximal effects of diltiazem and M 2 were each approximately 35-40% in GH-release assays, consistent with their partial agonist profiles in vitro.
This article has not been copyedited and formatted. The final version may differ from this version. Diltiazem is used to treat cardiovascular disorders such as angina pectoris, conjestive heart failure, chronic obstructive pulmonary disease, hypertension and coronary artery spasm (Abernethy and Schwartz, 1999; Chaffman and Brogden, 1985; Glossman and Striessnig, 1990) . Although diltiazem is thought to mediate these effects through blockade of L-type Ca 2+ channels, it is interesting to speculate whether or not GHSR1a receptors contribute to some of the therapeutic benefits of diltiazem therapy.
Peptidyl GHS, non-peptidyl GHS, and ghrelin itself are known to produce a number of beneficial cardiovascular effects including reductions in vascular resistance, vasodilation, increases in microvascular flow, increases in left ventricular ejection fraction and cardiac output, and cardioprotection against ischemia and cellular apoptosis in ischemiareperfusion injury paradigms (Nagaya et al, 2001; 2001b; 2001c; Benso et al, 2004; Cao et al, 2005; Bedendi et al, 2003; Baldanzi et al, 2002) , similar effects as occur with diltiazem administration. Diltiazem has been shown to provide cardioprotection against ischemia/reperfusion injury in rats, and it has been hypothesized that these protective effects are mediated through preservation of mitochondrial function by attenuating Na + overload through Na + channels (Takeo et al, 2003) . Possibly the cardioprotective effects of diltiazem in such models may be mediated, in part, through activation of GHSR1a receptors, which have anti-apoptotic effects in cardiomyocytes (Baldanzi et al, 2002) .
Besides the hypothalamus, GHSR1a receptors are widely distributed, and are expressed throughout the myocardium and vasculature, including ventricle and aorta, (Cao et al, 2005; Gnanapavan et al, 2002 , Guan et al, 1997 , where they could mediate some of the cardiovascular effects of GHS, ghrelin, and possibly diltiazem. It would be interesting to This article has not been copyedited and formatted. The final version may differ from this version. evaluate the possible contributions of GHSR1a receptors to the cardioprotective effects of diltiazem using GHSR1a-selective antagonists, or GHSR1a null mice.
Diltiazem has not been reported to elevate GH or cause weight gain clinically (McGraw et al, 1982) , and diltiazem was reported to inhibit food intake in SpragueDawley rats (Amer and Maher, 2005; de Beaurepaire and Freed, 1989) . We have not observed that diltiazem inhibits food intake, and may even modestly stimulate food intake in rats (unpublished observations). The apparent lack of effect chronic diltiazem on GH-release or food intake could be interpreted as a lack of support for the role of ghrelin agonists in these effects, however it is probably more likely due to the primary effects of diltiazem (i.e. blockade of Ca 2+ influx), which may impair GH-release ( Lussier et al, 1988) , and/or inadequate drug exposure (see Rovei et al, 1980; Sugihara et al, 1984; Chaffman and Brogden, 1985) given its potency for activating GHSR1a receptors (this paper) relative to its affinity for L-type Ca 2+ channels (Zobrist and Mecca, 1990; Glossmann and Striessnig, 1990) , and is also consistent with our observations that diltiazem is a partial agonist at GHSR1a receptors. Diltiazem peak plasma concentrations as high as 152 ng/ml were reported in healthy adult male volunteers (Zelis and Kinney, 1982) , comparable to significantly lower than the pEC 50 values reported here, depending upon the assay (Table 1) . These plasma concentrations are probably insufficient to mediate significant effects on GH-release or food intake given that these are peak rather than sustained concentrations, and do not take into account other factors that would reduce the free concentration of diltiazem at the target tissues such as protein binding (Yamano et al, 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. Diltiazem is extensively metabolized (Molden et al, 2000; Rovei et al, 1980; Sugihara et al, 1984; Sugawara et al, 1988) , and some of its metabolites, notably desacetyl diltiazem (M 1 ), reach plasma concentrations approaching 20-30% that of diltiazem itself in humans (Rovei et al, 1980; Sugihara et al, 1984 but all at lower affinity than diltiazem itself (Schoemaker et al, 1987) . The M 2 metabolite, which we found to be significantly more potent and efficacious as a GHSR1a agonist than diltiazem, had approximately 10-fold lower activity in L-type Ca 2+ channel binding and functional assays than diltiazem (Schoemaker et al, 1987) . Thus the structure-activity relationships for interactions of diltiazem and its metabolites with Ltype Ca 2+ channels and GHSR1a receptors diverge.
Given the results presented above, medicinal chemistry efforts using the diltiazem scaffold may yield potent GHSR1a agonists. Indeed, the diltiazem scaffold is amenable to medicinal chemistry, as shown previously (Floyd et al, 1992) . The divergence between GHSR1a activity and L-type Ca 2+ channel binding activity (Shoemaker et al, 1987) observed in the structural analogs tested here, demonstrates the potential for developing potent GHSR1a agonists lacking L-type Ca 2+ channel blocking activity from the diltiazem scaffold.
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